Trial Details
TERMINATEDBasic Information
| Clinical ID | c1130 |
|---|---|
| Identifier | NCT03893565 |
| Trial Title | Safety, Tolerability, Efficacy and Dose-response of GSK2831781 in Ulcerative Colitis |
| Trial URL | Visit Original Page |
Study Information
| Study Results | YES |
|---|---|
| Conditions | Colitis, Ulcerative |
| Interventions | DRUG: GSK2831781 - Double Blind Phase|DRUG: Placebo|DRUG: GSK2831781 - Open Label phase |
Participant Information
| Sponsor | GlaxoSmithKline |
|---|---|
| City | Northridge |
| Country/Region | United States |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | ADULT, OLDER_ADULT |
Study Design
| Study Type | INTERVENTIONAL |
|---|---|
| Phase | PHASE2 |
Time Information
| Start Date | 2019-05-06 |
|---|---|
| Primary Completion Date | 2021-05-17 |
| Completion Date | 2021-05-17 |